Email: cspc@cspc.cn

Contact Us

CSPC Pharmaceutical Group Co., Ltd.

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT RECOMBINANT FULLY HUMAN ANTI-βKlotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL

VOLUNTARY ANNOUNCEMENT RECOMBINANT FULLY HUMAN ANTI-βKlotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL

May 17, 2024

VOLUNTARY ANNOUNCEMENTRECOMBINANT FULLY HUMAN ANTI-βKlotho MONOCLONALANTIBODY DRUG (JMT202)OBTAINS CLINICAL TRIAL APPROVAL_00.png

VOLUNTARY ANNOUNCEMENTRECOMBINANT FULLY HUMAN ANTI-βKlotho MONOCLONALANTIBODY DRUG (JMT202)OBTAINS CLINICAL TRIAL APPROVAL_01.png

Previous: VOLUNTARY ANNOUNCEMENT OLAPARIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL

Next: VOLUNTARY ANNOUNCEMENT PERAMIVIR INJECTION OBTAINS DRUG REGISTRATION APPROVAL

Phone:

+86 311 8703 7015

Email:

Legal terms Privacy protection

Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |